Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
cotrifazid + mefloquine + quinine + sulfadoxine + pyrimethamine
- Development stage
- Discontinued
- Lead developer
- Unisanté
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
This entry refers to the therapeutic interventions evaluated in a randomized, open-label Phase 2 clinical trial (NCT00238719) conducted by the Center for Primary Care and Public Health (Unisante) at the University of Lausanne. The study assessed the safety and efficacy of **Cotrifazid**—a fixed-dose combination of rifampicin, isoniazid, sulfamethoxazole, and trimethoprim—compared to **mefloquine** and the standard treatment of **quinine plus sulfadoxine-pyrimethamine** (SP) for uncomplicated drug-resistant malaria in Papua New Guinea. Cotrifazid targets multiple pathways, including plasmodial RNA synthesis and the folate biosynthesis pathway. However, the trial demonstrated significant parasitological failure by day 14 for both *Plasmodium falciparum* and *Plasmodium vivax*, leading to the conclusion that Cotrifazid, in the tested formulation and regimen, is not an effective alternative for resistant malaria.
- Other names
- Cotrifazid vs Mefloquine or Quinine+SP for Resistant Malaria
02
Targets
RNAP (Bacterial dna-dependent RNA polymerase)DHFR (Dihydrofolate reductase)DHPS (Dihydropteroate synthase)InhAβ-Hematin
Beyond the preview
Go deeper on cotrifazid + mefloquine + quinine + sulfadoxine + pyrimethamine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on cotrifazid + mefloquine + quinine + sulfadoxine + pyrimethamine.